Revenue - Additional Information (Details) - USD ($)	12 Months Ended			36 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2022
Disaggregation Of Revenue [Line Items]
Contract with customer liability, revenue recognized	$ 20,600,000	$ 17,000,000.0	$ 11,500,000
Deferred revenue	19,221,000	27,153,000
Research, Collaboration and License Agreement | Eli Lilly
Disaggregation Of Revenue [Line Items]
Contract with customer liability, revenue recognized	12,300,000
Upfront payment received	7,200,000	$ 2,300,000	29,200,000	$ 31,500,000
Deferred revenue			$ 14,300,000	$ 14,300,000
Research, Collaboration and License Agreement | Eli Lilly | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-01-01
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation	$ 4,700,000
Revenue, remaining performance obligation, expected timing of satisfaction period	12 months
Research, Collaboration and License Agreement | Maximum | Eli Lilly
Disaggregation Of Revenue [Line Items]
Milestone payment threshold amount	$ 29,000,000
Low to mid-teens royalty threshold sales amount	125,000,000
Research, Collaboration and License Agreement | Minimum | Eli Lilly
Disaggregation Of Revenue [Line Items]
Mid-teens to mid-twenties royalty threshold sales amount	125,000,000
Various Other Agreements
Disaggregation Of Revenue [Line Items]
Deferred revenue	12,000,000.0
Various Other Agreements | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-01-01
Disaggregation Of Revenue [Line Items]
Revenue, remaining performance obligation	$ 8,800,000
Revenue, remaining performance obligation, expected timing of satisfaction period	12 months